Adding Finerenone to SGLT2 Inhibitors and Long-Term Kidney Outcomes in Diabetic Kidney Disease
Among patients with DKD receiving RASi and SGLT2i therapy, the addition of finerenone was associated with greater proteinuria reduction and a significant improvement in the post-initial dip eGFR slope, suggesting that TCT may offer an additional renoprotective strategy in DKD.